OCULAR THERAPEUTIX, INC (OCUL) Return on equity 2016–2025
OCULAR THERAPEUTIX, INC (OCUL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-40.6%FY2025 · since FY2016: -86.0% → -40.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -40.6% | +20.7 pp |
| FY2024 | -61.4% | +27.2 pp |
| FY2023 | -88.6% | +112.2 pp |
| FY2022 | -200.8% | -193.3 pp |
| FY2021 | -7.4% | +197.1 pp |
| FY2020 | -204.5% | — |
| FY2018 | -167.2% | +75.2 pp |
| FY2017 | -242.4% | -156.5 pp |
| FY2016 | -86.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More OCUL financial trends
OCUL RevenueOCUL Net incomeOCUL Net marginOCUL Gross profitOCUL Gross marginOCUL Operating incomeOCUL Operating marginOCUL Operating cash flowOCUL Free cash flowOCUL Capital expendituresOCUL Stock buybacksOCUL Dividends paidOCUL Total assetsOCUL Total liabilitiesOCUL Shareholders’ equityOCUL overview →